News and Announcements
Viralytics Ltd (ASX:VLA) – Shareholder and Investor Presentation
- Published April 03, 2013 12:07PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Viralytics Ltd (ASX:VLA) is an Australian ASX listed biotechnology cancer company focussed on developing viruses which selectively target cancer cells.
OVIERVIEW:
- Lead product is CAVATAK™ with broad anti-cancer activity
- CAVATAK™ program:
- Completed five Australian Phase 1 trials with 28 patients
- Current US Phase 2 trial in melanoma patients
- Planned Phase 1/2 UK trial in lung, prostate, bladder and melanoma cancer patients
- Potential low toxicity unlike traditional chemotherapies
- Achieved GMP manufacture
- Robust intellectual property/patent portfolio
- Big Pharma interest: 2011 US$1.0 billion Amgen/Biovex deal
- One of only 2 listed oncolytic virus companies globally
- Experienced Board/Management and Scientific team
To read the full ASX announcement, please download the document below.
Company Updates
The Index Approach in Early-Stage Venture Capital: Reconsidered
The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]
The Future Is Now: The Evolution of Dealflow with Wholesale Investor
If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]
Investability of a Startup: A Comprehensive Guide for Angels and High-Net Worth Investors
Venturing into the Startup Scene Let’s dive into the intriguing world of startups. It’s a thrilling ride, isn’t it? Like finding a pearl in an ocean, spotting a promising startup amidst a sea of businesses is no easy task. This guide aims to light the way, focusing on the “The Investability of a Startup: 7 […]
Backed By Leading Investment Groups and Family Offices
